Excellent clinic evaluation results which will start to generate revenue of ResAppDx into this sector and Medgate signing up as the first telehealth provider in Europe, these are all due in 3 months and push the pps back to 20c IMO.
RAP is a very unique product which doesn't have any technology limitation since this is totally objective so the doctors can't do what the product does. Hence, there are no other alternate stock in this sector which RAP provide, especially one that has all age demographic market which mean a massive revenue potential covering all the medical field in telehealth, clinic and ED and later DTC.
- Forums
- ASX - By Stock
- RAP
- Ann: Pre-Submission package lodged with the US FDA
Ann: Pre-Submission package lodged with the US FDA, page-42
-
- There are more pages in this discussion • 158 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
RAP (ASX) Chart |
Day chart unavailable